FDA Approved: SABRIL — Supplemental Application (Lundbeck Pharmaceuticals LLC)

View source ↗

Summary

FDA approved a supplemental application for Sabril (vigabatrin) submitted by Lundbeck Pharmaceuticals LLC.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Complex Partial Seizures
• Infantile Spasms
• Tuberous Sclerosis Complex

Drugs mentioned

• SABRIL (VIGABATRIN)

Snippet

SUPPL AP for SABRIL (VIGABATRIN)